The FDA co-development draft guidance for companion diagnostics and their associated therapeutics tackled a largely novel area of regulatory science for the practice of 21st Century medicine, but an Aug. 18, 2016, webinar clarified that a companion diagnostic (CDx) need not be a market-ready test, but need only offer "market-ready performance" to qualify for use in the therapeutic pivotal trial.